Evidence mapPaperPMID 39704162Full record

ArticleHaematologica2025

Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence.

Rajani P Brandsen, Roselie M H Diederen, Gizem Kocabas, Erfan Nur, Arjan Malekzadeh, Reinier O Schlingemann, Bart J Biemond

Abstract readScoping Review
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rajani P BrandsenDepartment of Ophthalmology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam. r.p.brandsen@amsterdamumc.nl.
Roselie M H DiederenDepartment of Ophthalmology, Amsterdam UMC, University of Amsterdam, Amsterdam.
Gizem KocabasDepartment of Ophthalmology, Amsterdam UMC, University of Amsterdam, Amsterdam.
Erfan NurDepartment of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Sanquin Research and Landsteiner Laboratory, Department of Blood Cell Research, Amsterdam.
Arjan MalekzadehMedical Library, Amsterdam UMC, University of Amsterdam, Amsterdam.
Reinier O SchlingemannDepartment of Ophthalmology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne.
Bart J BiemondDepartment of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sickle cell retinopathy (SCR) is a complication of sickle cell disease (SCD) and can drastically impair visual acuity. Screening for SCR is, therefore, recommended, but evidence for optimal screening frequency on an individual level is lacking. This scoping review mapped the current evidence on risk factors for SCR and sickle cell maculopathy (SCM). A literature search (in Medline [Ovid]), Embase [Ovid]), and Scopus) resulted in 67 included articles which covered demographic risk factors, genetic risk factors, systemic therapy, correlations with other forms of SCD-related organ damage, and hematologic risk factors. SCR risk factors include older age, male sex, HbSC genotype, hemolysis, and HbF% <15% (in HbSS) and increased blood viscosity (in HbSC). For SCM, risk factors are older age, HbSS genotype, and higher degree of hemolysis. The pathophysiology of SCR and SCM appears multifactorial, but distinct patterns emerge suggesting that vaso-occlusion and hemolysis cause SCM and NPSCR in HbSS, while hyperviscosity in HbSC leads to peripheral retinopathy. We recommend yearly screening for high-risk patients (older HbSC males) and triennial screening for low-risk patients (young females HbSS with HbF>15%) to ensure comprehensive yet proportionate ophthalmic care. However, future studies are needed on the role of interventions for SCR and the long-term consequences of SCM in order to evaluate and define appropriate screening schedules.

Indexed as

Anemia, Sickle CellMacular DegenerationRetinal DiseasesFemaleHumansMaleRisk Factors

Identifiers

PMID39704162
PMCPMC12050931

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.